Technical Analysis for EGRX - Eagle Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 56.83 -0.21% -0.12
EGRX closed down 0.21 percent on Wednesday, November 22, 2017, on 77 percent of normal volume.
Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical EGRX trend table...

Date Alert Name Type % Chg
Nov 22 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Nov 21 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -0.21%
Nov 20 NR7 Range Contraction -0.04%
Nov 20 Narrow Range Bar Range Contraction -0.04%
Nov 20 Spinning Top Other -0.04%
Nov 20 Bollinger Band Squeeze Range Contraction -0.04%
Nov 20 New Uptrend Bullish -0.04%
Nov 17 50 DMA Support Bullish -0.99%
Nov 16 NR7 Range Contraction -0.23%
Nov 15 Crossed Above 50 DMA Bullish 1.28%

Older signals for EGRX ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Basic chart:

Profile
Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company markets EP-1101 (argatroban) to treat heparin-induced thrombocytopenia. It develops EP-3101, a bendamustine ready to dilute (RTD) liquid and EP-3102, a bendamustine short infusion time RTD liquid for the treatment of chronic lymphocytic leukemia and non-Hodgkin's lymphoma; Ryanodex, a dantrolene to treat malignant hyperthermia; and EP-4104, a dantrolene that has completed a Phase I clinical study for the treatment of exertional heat stroke. The company also develops EP-5101 (pemetrexed) as RTD liquid, which is in pre-clinical formulation and toxicology studies to treat lung cancer; EP-6101, a bivalirudin RTU liquid formulation for the treatment of percutaneous transluminal angioplasty; and EP-2101 (topotecan) to treat ovarian, cervical, and small-cell lung cancers. Eagle Pharmaceuticals, Inc. was founded in 2007 and is based in Woodcliff Lake, New Jersey.
Is EGRX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 97.15
52 Week Low 45.05
Average Volume 297,196
200-Day Moving Average 69.2357
50-Day Moving Average 55.7392
20-Day Moving Average 55.349
10-Day Moving Average 55.9
Average True Range 2.4701
ADX 26.35
+DI 23.34
-DI 11.92
Chandelier Exit (Long, 3 ATRs ) 56.2597
Chandelier Exit (Short, 3 ATRs ) 58.8103
Upper Bollinger Band 58.4838
Lower Bollinger Band 52.2142
Percent B (%b) 0.74
BandWidth 11.327395
MACD Line 0.5601
MACD Signal Line 0.2637
MACD Histogram 0.2964
Fundamentals Value
Market Cap 862.05 Million
Num Shares 15.2 Million
EPS 5.96
Price-to-Earnings (P/E) Ratio 9.54
Price-to-Sales 3.34
Price-to-Book 4.96
PEG Ratio 0.95
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 58.78
Resistance 3 (R3) 58.79 58.14 58.46
Resistance 2 (R2) 58.14 57.65 58.14 58.35
Resistance 1 (R1) 57.49 57.34 57.17 57.48 58.24
Pivot Point 56.84 56.84 56.68 56.84 56.84
Support 1 (S1) 56.19 56.35 55.87 56.18 55.42
Support 2 (S2) 55.54 56.04 55.54 55.31
Support 3 (S3) 54.89 55.54 55.21
Support 4 (S4) 54.88